muscles. He felt that his legs were quite normal. He denied any sensory symptoms. There was no relevant family or drug history.
On examination, he had a prominent bluish/purple discolouration of the knuckles, thickening of the skin on the dorsum of the hands and a slight heliotrope facial rash. The facial muscles were slightly wasted and he had marked weakness and wasting of the sternomastoids, deltoids, spinatti, biceps and triceps, with relative preservation of distal muscles. All upper limb reflexes were grossly diminished or absent. In contrast, the bulk, power and reflexes in the lower limbs were entirely normal. All modalities of sensation were intact throughout.
The erythrocyte sedimentation rate was consistently normal (10-12 mm/hr) as were the serum muscle enzyme levels (CK 33.5 u/l-normal <50; aldolase 1. 4-normal <5 (fig (d) ), corresponding to the basophilic masses in the vacuoles seen by light microscopy.
The patient was treated with prednisone 20 mg tds and azathioprine 50 mg tds. On review one month later, he felt much better and his strength had improved. Over the succeeding month his skin rash gradually faded and the steroids were reduced to 30 mg daily. This resulted in a return of his symptoms and progressive exertional dyspnoea. Reinstitution of prednisone 20 mg tds again pro-272 duced significant improvement to his arm and shoulder strength and reduction of his dyspnoea. Further improvement in breathing followed addition of a beclomethasone inhaler to his regime. Attempts at steroids reduction some five months after starting treatment once more resulted in deterioration, particularly in his breathing but his condition had stabilised after six months of treatment on highdose steroids.
Unfortunately, in February 1978 he suddenly developed a right hemiplegia and dysphasia and eventually succumbed to a suppurative bronchopneumonia.
Discusson
Since Chou originally described "myxovirus-like structures and accompanying nuclear changes in a patient with chronic polymyositis", inclusion body myositis has emerged as an apparently distinct pathological entity. Furthermore, the clinical features in the majority of more than forty cases reported to date, have conformed to a pattern distinct from that normally encountered in autoimmune polymositis. [2] [3] [4] [5] [6] [7] Typically, inclusion body myositis presents with slowly progressive, sometimes asymmetrical, painless weakness which often affects the distal limb muscles as much, or even more prominently, than the proximal. Facial muscle weakness and dysphagia may be early manifestations. There has been some debate regarding the sex ratio in inclusion body myositis. Reviews of reported cases revealed a considerable male predominance, contrasting with the female predominance in autoimmune myositis.34 The condition tends to affect an older population than autoimmune polymyositis, although it may also occur in younger patients, who are more often female, and a bimodal age-sex distribution has been suggested.6 Serum muscle enzymes are generally normal, or only moderately raised.
Electromyography often reveals predominant changes of denervation with fibrillations and large prolonged duration polyphasic potentials with late components on volitional activity, but in some cases the changes may be predominantly myopathic.
Muscle biopsy findings in inclusion body myositis are said to be diagnostic.2-7 By light microscopy, 5-10% of the fibres reveal single or multiple membrane-lined vacuoles, often containing basophilic masses, and occasionally eosinophilic inclusions. The vacuoles are typically acid phosphatase negative, indicating that they are probably not autophagic. In addition to necrosis, phagocytosis and replacement of muscle by fat and fibrous tissue in chronic cases, most cases of inclusion body myositis reveal lymphocytic inflammatory cell infiltrates, although these may be sparse or even absent in some cases. The electronmicroscopic appearLane, Fulthorpe, Hudgson ances, however, are characteristic. There are cytoplasmic and intranuclear masses of randomly orientated filaments, reported to be between 10-25 nm in diameter and about 1-3,u in length, and membranous osmiophilic whorls within the vacuoles, which are believed to correspond to the basophilic masses seen by light microscopy.
Our patient thus conforms to the histopathological criteria for the diagnosis of inclusion body myositis. However, previous reviews have emphasised the absence of skin changes or other stigmata of collagen vascular disease in most cases and response to treatment in inclusion body myositis has been almost uniformly unsuccessful. The histopathological changes of inclusion body myositis have been reported, however, in patients with dermatomyositis8 9 scleroderma,'0 coeliac disease,'" and Sjogren's syndrome. '2 In addition several authors have reported modest clinical response to administration of steroids;45"1 but in other instances no treatment was given.34 Our patient undoubtedly had a collagen vascular disorder, with the typical skin changes of dermatomyositis, thyroid cytoplasmic antibodies and a chest radiograph and pulmonary diffusion disorder indicating interstitial pulmonary fibrosis of the type sometimes encountered in lupus erythematosus or systemic sclerosis. He showed substantial improvement in muscle strength with steroid treatment and relapsed transiently when the dose was decreased.
Clearly therefore, this case calls into question the status of inclusion body myositis as a separate nosological entity. It also emphasises the importance of at least attempting therapy in this condition.
